上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注当市场焦点都集中在创新药的底部公司挖掘时,一家创新生物制品龙头的基本面正在发生翻天覆地的变化,其不仅股价正在历史底部,并且几款核心产品都处于放量加速或上市快速放量的阶段,短期扭亏盈利路径清晰可见,这家公司便是康希诺生物。康希诺在2024年全年和2025Q1都交出了不错的业绩答卷,2024年公司营收8.46亿元(同比增长...
Source Link上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注当市场焦点都集中在创新药的底部公司挖掘时,一家创新生物制品龙头的基本面正在发生翻天覆地的变化,其不仅股价正在历史底部,并且几款核心产品都处于放量加速或上市快速放量的阶段,短期扭亏盈利路径清晰可见,这家公司便是康希诺生物。康希诺在2024年全年和2025Q1都交出了不错的业绩答卷,2024年公司营收8.46亿元(同比增长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.